Management Team

Stephen F. Ghiglieri , , , Interim Chief Executive Officer

Mr. Ghiglieri joins Galena Biopharma with more than 30 years in senior level finance and operations roles at both biotechnology and technology companies. Prior to Galena Biopharma, Mr. Ghiglieri served as CFO of MedData Inc., a private equity backed healthcare services company that was sold to Mednax, a publicly traded national medical group. Previously, he spent nearly 10 years at NeurogesX, ending his tenure as the Company’s Executive Vice President, Chief Operating Officer and CFO. Prior to that he served as the CFO of Hansen Medical, Inc., a medical device company. He also held senior level finance positions at two other healthcare companies: Oacis Healthcare Systems, Inc., and Oclassen Pharmaceuticals, Inc. Additionally, he was also the CFO and Corporate Secretary for two technology software companies: Avolent, Inc., and Andromedia, Inc. Mr. Ghiglieri began his career as an audit manager of PricewaterhouseCoopers, LLP. He received a Bachelor of Science in Business Administration from California State University, Hayward where he graduated Magna Cum Laude. Mr. Ghiglieri is also a Certified Public Accountant (inactive).

Bijan Nejadnik , , M.D. , , Executive Vice President and Chief Medical Officer

Dr. Nejadnik has more than 22 years of academic and industry experience, including twelve years with pharmaceutical and biotech companies including Jazz Pharmaceuticals, Johnson & Johnson, and Purdue Pharma. During his career, he has managed numerous clinical development teams and programs with a therapeutic focus in hematology-oncology, immunology and central nervous system diseases. In this capacity, Dr. Nejadnik has successfully developed numerous biologics and small molecules, advancing these agents towards Biologics License Application (BLA) and New Drug Application (NDA) submissions. Dr. Nejadnik joins Galena from Jazz Pharmaceuticals where he was the Executive Director, Hematology-Oncology and led the clinical team towards a recently filed NDA. Prior to Jazz, he spent seven years at Johnson & Johnson working on numerous compounds in early and late stage registrational trials in immunology and oncology. Dr. Nejadnik spent more than 13 years in teaching, research and caring for patients at world-renowned academic institutions including Stanford University School of Medicine, Johns Hopkins University School of Medicine, University of California, Davis, and State University of New York, Syracuse. Dr. Nejadnik graduated from the University of Louvain in Belgium for both his undergraduate degree in premedical studies, graduating Summa Cum Laude, and his medical degree, graduating Magna Cum Laude. He completed his internship and residency programs specializing in internal medicine focused on hematology-oncology at the University of Louvain and Oregon Health Sciences University. He completed his fellowships at Cornell University’s Weill Medical College and Johns Hopkins University School of Medicine. Dr. Nejadnik has led or participated in more than 20 peer-reviewed publications.

Thomas J. Knapp , , Esq , , Interim General Counsel and Corporate Secretary

Mr. Knapp joined Galena in 2015 as our Interim General Counsel and Corporate Secretary. Previously, he was the Executive Vice President, Chief Legal Officer and Corporate Secretary of Sucampo Pharmaceuticals, Inc., a publicly held pharmaceutical company, where he was responsible for domestic and global legal matters, litigation, corporate governance and compliance, intellectual property and government affairs and was a director of Sucampo AG, the Swiss subsidiary of Sucampo Pharmaceuticals, Inc. Prior to joining Sucampo, he was engaged in the private practice of law in the Washington, D.C. area after having served as the Vice President, General Counsel and Corporate Secretary of Northwestern Corporation, Washington, D.C., one of the largest publicly-owned utilities servicing the upper Midwest and northwestern United States. Mr. Knapp has more than 20 years of experience as General Counsel or Assistant General Counsel of publicly held corporations. He holds a B.A. degree from the University of Illinois at Urbana, and a J.D. from Loyola University Chicago School of Law.

Remy Bernarda , , IRC , , Senior Vice President, Investor Relations & Corporate Communications

Ms. Bernarda joined Galena full time in May 2013 after consulting for the company for two years prior. She brings over 20 years of experience in finance and corporate communications, with half her career spent in investor relations and corporate communications for biotechnology companies. Ms. Bernarda was a member of the inaugural group to fulfill the career requirements and pass the Investor Relations Charter (IRC) examination in 2016. Before Galena, she was a consultant for numerous biotechnology companies on their investor relations programs. Prior to consulting, Ms. Bernarda was Director, Investor Relations at Hana Biosciences, a small cap biotechnology company. She began her career on Wall Street, working in the institutional sales and trading departments at Goldman Sachs and Knight Equity Markets, and in investment banking at Bear Stearns. She holds an M.B.A. and a B.S. degree in Business Administration with minors in Marketing from Pepperdine University. Ms. Bernarda remains active with the National Investor Relations Institute , served on the Body of Knowledge Committee, and was a member of the Silicon Valley Chapter Board of Directors for four years.

John T. Burns , , CPA , , Vice President, Finance and Corporate Controller

Mr. Burns joined Galena in May 2013 and has held various positions of increasing responsibility during his tenure. Prior to Galena, Mr. Burns was a Securities and Exchange Commission (SEC) Reporting Manager at Pixelworks, Inc., (NASDAQ: PXLW), a company focused on video display processing technology. He began his career in public accounting at Moss Adams LLP where he worked with private and public technology companies providing business assurance services. Mr. Burns was previously on the Advisory Board for Novate Medical Technologies and currently offers financial and market guidance to a private, medical device start-up company. He holds a Master of Accounting and a Bachelor of Science degree in Finance from Tulane University. Mr. Burns is an active Certified Public Accountant.

Email Alerts

Email Address *
Mailing Lists *





Investor Contact

Remy Bernarda, IRC

SVP, Investor Relations & Corporate Communications

ir@galenabiopharma.com